Ovulation Induction With Clomiphene Citrate and Dexamethasone

Overview

The purpose of this study is to determine if the addition of dexamethasone to clomiphene citrate will increase the pregnancy rate of intrauterine insemination (IUI) cycles.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: June 2015

Detailed Description

For decades clomiphene citrate (CC) has been the first line therapy for ovulation induction in anovulatory or oligoovulatory women, and for superovulation in women with unexplained infertility or partners with mild sperm abnormalities. While approximately 80% of patients achieve ovulation with CC, less than half conceive. Pregnancy is achieved in approximately 10% of ovulatory cycles. Addition of dexamethasone to CC has been shown to result in pregnancy rates of 21-40% in CC-resistant women (defined as patients failing to ovulate on CC alone). A subsequent randomized controlled trial demonstrated higher pregnancy rates in patients with unexplained infertility undergoing intrauterine insemination (IUI) with CC + dexamethasone compared to those taking CC alone. In light of the relatively high pregnancy rates achieved in previous trials, we hypothesize that dexamethasone as an adjunct to CC will increase the ovulation rate and pregnancy rate for all appropriate candidates for IU with a standard CC regimen. Our study is designed to randomize patients undergoing ovulation induction with IUI into two groups: one consisting of a standard CC regimen, and the other consisting of the same CC regimen with the addition of daily dexamethasone. The primary outcome measure is pregnancy.

Interventions

  • Drug: Placebo
    • A placebo with similar appearance to dexamethasone will be given with a standard regimen of clomiphene citrate (100mg/day oral for 5 days) for ovulation induction
  • Drug: Dexamethasone
    • Oral dexamethasone will be added to a standard regimen of clomiphene citrate (100mg/day oral for 5 days) for ovulation induction

Arms, Groups and Cohorts

  • Experimental: Clomiphene plus dexamethasone
    • Oral dexamethasone will be added to clomiphene citrate
  • Placebo Comparator: Clomiphene plus placebo
    • A placebo of dexamethasone will be given with clomiphene citrate

Clinical Trial Outcome Measures

Primary Measures

  • Pregnancy
    • Time Frame: 12 weeks
    • Determined by serum hCG measurement

Secondary Measures

  • Clinical pregnancy
    • Time Frame: 12 weeks
    • Determined by ultrasound

Participating in This Clinical Trial

Inclusion Criteria

  • Active duty military members or dependents seeking infertility treatment at Brooke Army Medical Center – primary or secondary infertility – candidate for intrauterine insemination (IUI) Exclusion Criteria:

  • Severe male factor infertility (total motile sperm count <10 million/mL) – Bilateral fallopian tube obstruction – Diminished ovarian reserve (baseline follicle stimulating hormone > 20) – History of clomiphene resistance as determined by a Clomid challenge test or prior non-ovulatory cycles while taking clomiphene – Known or suspected hypopituitarism or hypothalamic amenorrhea – Six or more prior therapeutic CC cycles without a pregnancy – Diabetes – Renal impairment, hepatitis, hepatic cirrhosis, or myasthenia gravis – Osteoporosis – Cataracts or glaucoma – Congenital Adrenal Hyperplasia, Cushing's disease, or any condition requiring chronic corticosteroid use

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 40 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • San Antonio Military Medical Center
  • Provider of Information About this Clinical Study
    • Principal Investigator: Jeremy King, Reproductive Endocrinologist – San Antonio Military Medical Center
  • Overall Official(s)
    • Jamie Massie, MD, Principal Investigator, San Antonio Military Medical Center
  • Overall Contact(s)
    • Brandy M Butler, MD, 210-916-2168, brandy.m.butler2.mil@mail.mil

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.